**CURRICULUM VITAE**

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ December 8, 2021

**Daime Nieves, ARNP MSN, CPNP-PC , MD (Cuba)**

**DEMOGRAPHIC AND PERSONAL INFORMATION**

**Personal Data**

Business Address: University of South Florida Multispecialty Clinic

 601 5th street South Suite 304

 St. Petersburg FL, 33701

Tel: (727)320-2042

Fax: (727) 767-3285

E-mail: daime@health.usf.edu

**Education and Training**

Doctoral/graduate

07/1989- 08/1995 M.D., Institute of Higher Education of Medicine, Cuba

**Postdoctoral**

09/1995- 12/1998 Resident, Pediatrics, Hospital Pediátrico Provincial “Eduardo Agramonte Pina”,

Camaguey, Cuba

08/2010-12/2011 RN, ASN, St Petersburg Community College

01/2015- 12/2018 APRN, MSN University of South Florida

**Professional Experience**

1998- 2004 Assistant Professor, Department of Microbiology, Institute of Higher Education of Medicine, Camaguey, Cuba

1998- 2004 Staff Physician, Emergency Center, Hospital Pediátrico Provincial “Dr. Eduardo Agramonte Pina”, Camaguey, Cuba

2001-2004 Staff Physician, Multidisciplinary Clinic, “ Tula Aguilera”, Camaguey

2011- 2014 RN staff, Baycare Health System, Morton Plant, Clearwater, Florida

* Developed care plans and protocols for chemotherapy patients

2014- 2019 RN Supervisor, USFPG Division of Allergy, Immunology, and Nephrology, Tampa, FL

* Direct daily clinic operations
* Create treatment and procedures’ protocols
* Direct participation in management of patients with anaphylactic reactions
* Performed antibiotic, venom, vaccine and food challenges
* Research mentor

2019- current APRN, USFPG Division of Allergy, Immunology

2019- current A&I Sponsored clinical trials manager

2019- Co-Investigator- HYQVIA in Pediatric Subjects with Primary Immunodeficiency Diseases

2019- current Co-Investigator – Clinical phase 3 study to monitor the safety, tolerability and efficacy of subcutaneous human immunoglobulin( Cuatquig) administered at modified dosing regiments in patients with Primary Immunodeficicnecy Diseases.

2020- current Co- Investigator- Single Arm, Open-Label, Multicenter, Registry Study of Revcovi (elapegademase-lvlr)Treatmentin ADA-SCID Patients Requiring Enzyme Replacement Therapy

2021- current Co- Investigator- A Phase 2/3, Two-Part, Open-Label, Dose-Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Children 6 Months to Less Than 12 Years of Age

**PUBLICATIONS**:

***Science Publications***

1. **Nieves, D.** Myocardiopathies in adolescent. Rev Cubana Pediatria 2001;73(2):100 - 122
2. **Nieves, D.** Intraventricular catheterism in patients with severe cranio-encephalic trauma. Rev Cubana Pediatria 2001;71(5):115-22

***Co-author***

1. Hyalorunidase- Facilitated High- Dose Subcutaneous IgG Effectively Controls Parvovirus B19 Infection in a Pediatric Cardiac Transplant Patient With Severe T-Cell Lymphopenia.
2. X-Linked Agammaglobulinemia Presenting as Neutropenia: Case Reprt and an Overvie of Literature. Front Pediatr. 2021 Jun 28;9:633692. doi: 10.3389/fped.2021.633692. eCollection 2021.PMID: 34262886
3. Case Report: A Novel Pathogenic Missense Mutation in FAS: A Multi-Generational Case Series of Autoimmune Lymphoproliferative Syndrome. Front Pediatr. 2021 Mar 18;9:624116. doi: 10.3389/fped.2021.624116. eCollection 2021.PMID: 33816397

***Sponsored Studies with University of South Florida (2020-2021)***

1. 2020- current Co- Investigator- Single Arm, Open-Label, Multicenter, Registry Study of Revcovi (elapegademase-lvlr)Treatmentin ADA-SCID Patients Requiring Enzyme Replacement Therapy
2. A Phase 2/3, Two-Part, Open-Label, Dose-Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Children 6 Months to Less Than 12 Years of Age

***Sponsored Studies with University of South Florida (2019)***

1. Co-Investigator- HYQVIA in Pediatric Subjects with Primary Immunodeficiency Diseases
2. 2019- current Co-Investigator – Clinical phase 3 study to monitor the safety, tolerability and efficacy of subcutaneous human immunoglobulin( Cuatquig) administered at modified dosing regiments in patients with Primary Immunodeficicnecy Diseases.

***Sponsored Studies with University of South Florida (2018)***

1. Study Nurse. Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic of HYQVIA in Pediatric Subjects with Primary Immunodeficiency Diseases

***Sponsored Studies with the Heart and Vascular Institute of Florida (2012)***

1. AstraZeneca, A randomized, double-blind, parallel group, multicenter phase IIIb study to compare

Ticagrelor with Clopidogrel treatment on the risk of cardiovascular death, Myocardial infarction and ischemic stroke in patients with established Peripheral Artery Disease( Euclid)

1. Sanofi. Long term safety and tolerability of REGN727/ SAR236553 in high cardiovascular risk patients with hypercholesterolemia not adequately controlled with their lipid modifying therapy: a randomized, double- blind, placebo- controlled study( Odyssey)
2. Lantheus: A phase 3. Open Label. Multicenter Study for the Assessment of Myocardial prefusion using Positron Emission Tomography (PET) Imaging of Flurpiridaz F18 injection in patients with suspected or known Coronary Artery Disease( CAD)
3. A Prospective, Multicenter, Single Blind, Randomized, Controlled Trial Comparing the Moxy Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal Arteries (Levant 2)
4. Spirit Prime Clinical Trial: A clinical evaluation of the Xience Prime LL. Everolimus Eluting Coronary Stent system.
5. Spirit small vessel/ Long lesion Clinical Trial. A Clinical of the ABT Everolimus Eluting Coronary Stent System

***Sponsored Studies with DMI Research (2011-2012)***

1. Purdue Pharma: ONU3704 / 3705. Chronic low back pain
2. Abbott: M11-313. Hidradenitis suppurativa
3. Lilly: H9B-MC-BCDS. Systemic lupus erythematosus
4. Pfizer: A3921024. Rheumatoid Arthritis
5. NIH: IRC-003. FLU
6. Novartis: CACZ885H2361. Gouty arthritis
7. Novartis: CAIN 457 F2302. Rheumatoid Arthritis
8. Pfizer: A3921024.  Rheumatoid Arthritis
9. Takeda: TMX67-30. Gout

**CLINICAL ACTIVITIES**

**Certification**

Medical

1995 Cuban Medical License

1998 Pediatric Residence completed- License ( Cuba)

2012 Registered Nurse

2019 Certified Pediatric Nurse Practitioner

**Boards**

2011, National Council Licensure Examination- Registered Nurse

2019 Pediatric Nursing Certification Board (PNCB)

**Clinical Responsibilities**

1998 – 2004 Staff Physician, Emergency Center, Hospital Pediátrico Provincial “Dr. Eduardo Agramonte Pina”, Camaguey, Cuba. 6 nights per month

**Clinical Program Building / Leadership**

1998- 2004 Supervision of med students and residents, Pediatric Hospital Eduardo Agramonte Pina, Camagüey, Cuba

1998-2004 Supervision of 12 med students and 6 residents on inpatient ward rotations in Hospital Pediátrico Eduardo Agramonte Pina, Camaguey, Cuba

2014-2019 RN Supervisor, USFPG Division of Allergy, Immunology, and Nephrology, Tampa, FL

2019- current Sponsored Studies team Supervisor, USF Division of Allergy, Immunology, St Petersburg, FL

**EDUCATIONAL ACTIVITIES**

**Teaching**

Classroom instruction

1998-2004 Microbiology, Institute of Higher Education of Medicine, Lecturer in 5 sessions, Camaguey, Cuba

2020- 2021 Preceptor- USF College of Nursing- Advanced Practice Registered Nurse Program

**SERVICES**

2018- current Member of USF Research Committee

**RECOGNITION**

**Awards, Honors**

1995 Golden Student Award, Institute of Higher Education of Medicine, Camaguey, Cuba